Watchlist Price Alert

Tarsus Pharmaceuticals In... (TARS)

NASDAQ: TARS · Real-Time Price · USD

44.82

-2.32 (-4.92%)

At close: May 09, 2025, 3:59 PM

44.64

-0.40%

After-hours: May 09, 2025, 05:10 PM EDT

-4.92% (1D)

Bid	44.64
Market Cap	1.88B
Revenue (ttm)	233.67M
Net Income (ttm)	-104.94M
EPS (ttm)	-2.7
PE Ratio (ttm)	-16.6
Forward PE	36.15
Analyst	Buy

Ask	46.2
Volume	416,247
Avg. Volume (20D)	685,050
Open	47.11
Previous Close	47.14
Day's Range	44.59 - 47.32
52-Week Range	20.08 - 57.28
Beta	0.94

About TARS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TARS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TARS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Tarsus Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $78.33M exceeds estimates by $6.71M, with 183.68% YoY growth.

EPS of -0.64 misses estimates by -0.01, with 36.63% YoY growth.

Why Price Moved

1 week ago

-5.84%

Tarsus Pharmaceuticals shares are trading lower fo... Unlock content with Pro Subscription

2 months ago

-9.33%

Shares of Tarsus Pharmaceuticals are trading lower. The company reported Q4 financial results.

News

1 week ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Office...

1 week ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago.

1 week ago · zacks.com

Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?

The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

2 months ago · seekingalpha.com

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project T...

2 months ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwa...

2 months ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.